Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Interferon alfa-2b may interfere with the growth of the cancer cells. Thalidomide
may stop the growth of cancer by stopping blood flow to the tumor. It is not yet known if
interferon alfa-2b is more effective with or without thalidomide in treating kidney cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa-2b with
or without thalidomide in treating patients who have previously untreated metastatic or
unresectable kidney cancer.